- Previous Close
14.14 - Open
14.00 - Bid 14.00 x --
- Ask 13.72 x --
- Day's Range
13.68 - 14.40 - 52 Week Range
12.34 - 31.75 - Volume
41,581 - Avg. Volume
80,344 - Market Cap (intraday)
715M - Beta (5Y Monthly) 0.97
- PE Ratio (TTM)
175.00 - EPS (TTM)
0.08 - Earnings Date Feb 13, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
16.00
ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, in vitro diagnostics, and biomanufacturing in Norway, Germany, Lithuania, France, Italy, rest of Europe, the United States, and internationally. The company offers shrimp alkaline phosphatase for cleanup prior to Sanger sequencing and next generation sequencing processes; cod UNG for use in viral and other molecular diagnostic assays; salt active nuclease for the removal of nucleic acids during manufacturing of viral vectors, recombinant proteins, and other reagents; double-strand specific DNases and derived kits for the removal of double stranded DNA; DNA/RNA polymerases for technology development for life science, molecular diagnostics, NGS, and synthetic biology; proteinase for microbiological diagnostics and liquid biopsies; and ligases for joining nucleic acids. It serves the molecular tools research and diagnostics, and biomanufacturing markets. The company was formerly known as Biotec Pharmacon ASA and changed its name to ArcticZymes Technologies ASA in June 2020. ArcticZymes Technologies ASA was founded in 1990 and is headquartered in Tromsø, Norway.
www.arcticzymes.comRecent News: AZT.OL
View MorePerformance Overview: AZT.OL
Trailing total returns as of 2/7/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AZT.OL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AZT.OL
View MoreValuation Measures
Market Cap
715.00M
Enterprise Value
481.82M
Trailing P/E
175.00
Forward P/E
277.78
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
6.90
Price/Book (mrq)
2.24
Enterprise Value/Revenue
4.45
Enterprise Value/EBITDA
34.38
Financial Highlights
Profitability and Income Statement
Profit Margin
4.18%
Return on Assets (ttm)
-0.27%
Return on Equity (ttm)
1.48%
Revenue (ttm)
110.76M
Net Income Avi to Common (ttm)
4.63M
Diluted EPS (ttm)
0.08
Balance Sheet and Cash Flow
Total Cash (mrq)
242.12M
Total Debt/Equity (mrq)
2.80%
Levered Free Cash Flow (ttm)
-12.51M